Weaponising your immune system
Tuesday, 7 August 2018
By Bernd Struben
- More than a pipe dream
- ‘No End in Sight for Drought Woes’
Two weeks ago today, I wrote to you about one of the most striking research reports I’ve read all year.
It was put together by Harje Ronngard, editor of the small-cap advisory service Wealth Eruption. You may also know Harje as the editor of our free daily e-letter, Money Morning.
His new report stood out to me for two reasons.
First, there’s a potentially lucrative investment angle attached to it. Very lucrative. And part of my beat at Port Phillip Insider is to make sure you’re aware of any breaking opportunities our editors uncover. Whether you choose to pursue that opportunity is, of course, up to you.
The second reason Harje’s new report grabbed my attention is its focus on a potential medical breakthrough Harje calls ‘the living drug’.
In his words it could, ‘eradicate mankind’s deadliest diseases including cancer, HIV, arthritis and Multiple Sclerosis.’
Having lost my mother, my father-in-law, and more acquaintances than I care to count to cancer I wanted to share his report with you right away.
As you may recall, I was a bit premature in doing so. It turns out I’d gotten my hands on an early draft. Harje and our compliance team still needed to complete some research before we could publish it.
The good news is that’s all done now. As of this morning, you can access Harje’s ground breaking research report here.
I won’t give too much away. It’s worth having a full read yourself. Just set aside a little quiet time to do it justice.
But here’s a little teaser on ‘the living drug’ from Harje:
‘For centuries, doctors and scientists have tried — and failed — to beat our most dangerous known diseases by targeting and treating the condition itself.
‘The living drug is different.
‘See, instead of trying to treat the disease, a small group of Californian scientists have developed a way to “weaponise” the immune system and turn ordinary human T-cells into disease destroying machines.’
According to Harje, scientists are studying how they can utilise the living drug to treat more than 100 autoimmune diseases.
And this isn’t some small-time experiment.
It’s backed by billion-dollar pharmaceutical companies including Pfizer, Bayer and Novartis.
Those big players should benefit handsomely if the research pans out as hoped. But share price gains in blue chip companies tend to be limited by the simple fact that they are already billion dollar companies.
That’s why Harje has identified one particular small-cap biotech stock at the very centre of this breaking research. This tiny company could see its share price rocket by 2,000% or more as the research progresses to human clinical trials.
And that all could begin unfolding inside the next few weeks.
Now to the markets.
Overnight the Dow Jones Industrial Average closed up 39.60 points, or 0.16%.
The S&P 500 gained 10.05 points, or 0.35%.
In Europe the Euro Stoxx 50 index finished up 0.90 points, or 0.03%. Meanwhile, the FTSE 100 gained 0.06%, and Germany’s DAX fell 17.55 points, or 0.14%.
In Asian markets, Japan’s Nikkei 225 is up 143.12 points, or 0.64%. China’s CSI 300 is up 1.50%.
In Australia, the S&P/ASX 200 is down 26.78 points, or 0.43%.
On the commodities markets, West Texas Intermediate crude oil is US$68.91 per barrel. Brent crude is US$73.75 per barrel.
As you likely know, Donald Trump wants to see the price of oil come down…by a lot. In particular he wants to ensure US voters are paying a lot less for petrol before the November mid-term elections on 6 November.
And love him or hate him, when the Donald talks, people — and nations — listen.
In this case it’s the Saudis, who’ve upped their exports of crude to the US to the highest level in 15 months.
‘The world’s largest oil exporter loaded 1 million barrels a day onto tankers bound for the U.S. in July, according to preliminary vessel-tracking data compiled by Bloomberg. That’s a 36 percent jump from June and the single biggest monthly flow to the U.S. since April 2017.
‘The surge in flows might help officials in Riyadh to argue that they’re responding after U.S. President Donald Trump blamed OPEC for high oil prices and called on Saudi Arabia to add supply. It also helps replace barrels that have been lost by the collapse in Venezuela…’
You can see the spike in exports below:
Click to enlarge
If tensions boil over between Iran and the US, there’s certainly potential for crude prices to spike. But make no mistake. There is plenty of supply to meet global demand. And as the US continues to iron out the kinks in its delivery system, Trump should get his wish and see oil back below US$60 per barrel.
Turning to gold, the yellow metal is trading for US$1,208.50 (AU$1,636.43) per troy ounce. Silver is US$15.31 (AU$20.73) per troy ounce.
One bitcoin is worth US$6,938.50.
The Aussie dollar is worth 73.85 US cents.
More than a pipe dream
We’ll continue on with our medical theme. But we’ll leave the breaking trend of the ‘living drug’ behind and instead look at one of the oldest drugs known to man.
Records show cannabis has been used by man for almost 5,000 years, dating back to Chinese Emperor Shen Nung in 2727 B.C. Yet scientists have only recently begun to properly explore the drug’s enormous medicinal potential.
That’s because throughout the 20th Century government’s around the world insisted marijuana was little more than an addictive drug. One that will rot your brain. The US led that propaganda drive. And it managed to convince most Americans that medicinal marijuana was a, erm, pipe dream.
This saw the majority supporting the illegality of cannabis. But as you can see in the graph below, that attitude has been steadily changing.
More than 60% of Americans now support the legalisation of not just medicinal but also recreational marijuana:
Click to enlarge
At the moment, nine US states have legalised the sale of recreational weed to adults. Many more have legalised medicinal marijuana.
According to a report by Arcview Market Research and BDS Analytics, the combined legal cannabis market in the US will reach US$11 billion (AU$14.9 billion) this year. And it’s only just getting rolling.
Those kinds of figures have attracted the attention of numerous big name investors. William Wrigley Jr II is only the latest.
‘The scion of a family that made a fortune in chewing gum is moving into pot.
‘William Wrigley Jr. II, who helped orchestrate the sale of his family’s business to Mars Inc. in 2008, led a $65 million investment round for Surterra Wellness, a medical cannabis startup in Georgia with licenses to operate in Florida and Texas. The funding brings the total raised so far to $100 million, according to Surterra…
‘“When I understood the massive benefits, it really changed my mind about the industry,” Wrigley said in an interview, his first public comments about the investment. “You don’t see too many opportunities to have that kind of an impact in an industry that is being created from scratch.”’
Getting in on an industry being created from scratch is precisely what drew Sam Volkering’s attention to pot stocks last year.
He recommended his first medicinal marijuana stock to readers of Australian Small-Cap Investigator in February 2017. It’s currently up 280% from Sam’s recommended buy-in price.
That’s not to say every one of his pot stock tips has shot the lights out…yet. The biggest loser at the moment is down 34%, though Sam remains confident its fortunes will take a turn for the better.
In a recent report, Sam highlights his current favourite pot stock play. One he believes could see its share price rocket by 495%.
Finally, here’s the latest on the East Coast drought from The Australian Tribune:
‘No End in Sight for Drought Woes’
‘For most Australians a lengthy dry spell is little more than an inconvenience.
‘It may mean your lawn turns yellow if you’re no longer allowed to use the sprinklers. And you might find yourself reduced to a bucket of water to clean the family car. But it’s unlikely to affect your job.
‘For Australia’s farmers, the story is starkly different.
‘If it were…’
If you’re fed up with sanitised, politically correct dogma cut and pasted from one mainstream source to another, then The Australian Tribune is for you.
And it’s absolutely free.
Sign up here to get The Australian Tribune delivered free to your inbox five days per week.
You can visit our website at https://www.theaustraliantribune.com.au/ to read the complete article above now.